Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Structure-modifying agents for osteoarthritis: an update.

Pascal Richette1, Thomas Bardin

  • 1Fédération de Rhumatologie, Lariboisière Teaching Hospital, 2 rue Ambroise-Paré, 75010 Paris cedex 10, France. pascal.richette@lrb.ap-hop-paris.fr

Joint Bone Spine
|February 11, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update.

Joint bone spine·2026
Same author

Reliability of ultrasound assessment of elementary lesions in psoriatic arthritis and development of a reference dactylitis atlas.

Rheumatology (Oxford, England)·2026
Same author

Urate Lowering and Cardiovascular Risk-Extending the Benefits of a Treat-to-Target Strategy in Gout.

JAMA internal medicine·2026
Same author

Screening for transthyretin amyloid cardiomyopathy in patients with musculoskeletal symptoms: Red flags in the rheumatology/orthopedics practice setting.

Joint bone spine·2025
Same author

Transcutaneous auricular vagus nerve stimulation versus sham stimulation in patients with erosive hand osteoarthritis (ESTIVAL): a randomised, multicentre, double-blind, sham-controlled trial.

The Lancet. Rheumatology·2025
Same author

Photon-counting CT of Bone Erosions Induced by Gouty Tophi.

Radiology·2025
Same journal

Greater trochanteric bursal distension with intra-bursal rice bodies: an unusual MRI presentation.

Joint bone spine·2026
Same journal

Evaluating the Impact of a Rheumatologist-led Comorbidity Review in Patients with Inflammatory Arthritis.

Joint bone spine·2026
Same journal

What cumulative glucocorticoid dose should trigger sparing strategies in polymyalgia rheumatica?

Joint bone spine·2026
Same journal

Multimodal imaging evaluation of the entheses in spondyloarthritis.

Joint bone spine·2026
Same journal

Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update. What's new?

Joint bone spine·2026
See all related articles

Chondroprotective drugs aim to prevent or repair joint damage in osteoarthritis. However, despite promising lab results, no drug has yet demonstrated clinically significant structure-modifying effects in human osteoarthritis patients.

Area of Science:

  • Orthopedics and Rheumatology
  • Pharmacology

Background:

  • Osteoarthritis (OA) is a degenerative joint disease characterized by cartilage breakdown.
  • Chondroprotective and structure-modifying drugs are sought to halt OA progression.
  • Current evaluation relies on measuring joint space narrowing on radiographs.

Purpose of the Study:

  • To review the concept and evaluation of structure-modifying drugs for osteoarthritis.
  • To assess the evidence for clinically meaningful structure-modifying effects in humans.

Main Methods:

  • Review of radiological techniques for measuring joint space width in knee and hip OA.
  • Analysis of studies evaluating slow-acting OA drugs for structure-modifying potential.

Main Results:

Related Experiment Videos

  • Radiographic joint space width measurement is the standard for assessing structural changes.
  • Various techniques exist for precise joint space width quantification.
  • Despite in vitro promise, no drug has shown proven structure-modifying efficacy in human OA.

Conclusions:

  • The definition of chondroprotective and structure-modifying drugs is established.
  • Radiographic assessment is the primary method for evaluating structural modification in OA.
  • Clinically meaningful structure-modifying effects of drugs in human OA remain unproven.